Harvard Bioscience
HBIO
81 hedge funds and large institutions have $83.6M invested in Harvard Bioscience in 2013 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
3% more funds holding
Funds holding: 79 → 81 (+2)
2% more capital invested
Capital invested by funds: $82.4M → $83.6M (+$1.28M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
72% less call options, than puts
Call options by funds: $128K | Put options by funds: $454K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$852K |
| 2 |
AIC
Atlantic Investment Company
Atlanta,
Georgia
|
+$717K |
| 3 |
VDBMI
Van Den Berg Management I
Austin,
Texas
|
+$613K |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
+$529K |
| 5 |
MOACM
Mutual of America Capital Management
New York
|
+$432K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.13M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$2.42M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$601K |
| 4 |
HMC
Harbert Management Corporation
Birmingham,
Alabama
|
-$555K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$487K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Barclays
London,
United Kingdom
| $5K | -$63.1K | -1,605 | -91% |
|
|
DADC
77
D.A. Davidson & Co
Great Falls,
Montana
| $4K | – | – | – |
|
|
LTFS
78
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
|
TRCT
79
Tower Research Capital (TRC)
New York
| $1K | +$669 | +17 | New |
|
80
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.22K | +31 | New |
|
81
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $70 | -$1.3K | -33 | -2% |
|
|
82
Fidelity Investments
Boston,
Massachusetts
| – | -$7.13M | -198,854 | Closed |
|
|
KCM
83
Kennedy Capital Management
St Louis,
Missouri
| – | -$601K | -16,865 | Closed |
|
|
SIP
84
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$131K | -3,684 | Closed |
|
|
QCM
85
Quaker Capital Management
Canonsburg,
Pennsylvania
| – | -$126K | -3,535 | Closed |
|
86
D.E. Shaw & Co
New York
| – | -$67K | -1,858 | Closed |
|
87
Principal Financial Group
Des Moines,
Iowa
| – | -$50K | -1,390 | Closed |
|
88
BNP Paribas Financial Markets
Paris,
France
| – | -$49.8K | -1,389 | Closed |
|
HBIO Hedge Fund Activity: Q3 2013 in Review
81 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2013, worth a combined $83.6M — up 1.6% from $82.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new HBIO positions and 7 closed out — a net gain of 3 holders — while 33 added to existing stakes and 22 trimmed.
The largest buyer was Levin Capital Strategies, opening a new position worth an estimated $852K. The largest seller was Fidelity Investments, exiting entirely with an estimated $7.13M sold.
- 81 institutional investors held Harvard Bioscience (HBIO) as of Q3 2013, up from 79 in Q2 2013.
- Funds reported $83.6M of Harvard Bioscience stock for Q3 2013, up 1.6% quarter-over-quarter.
- 10 funds opened new Harvard Bioscience positions in Q3 2013 and 7 closed out, a net change of +3 holders.
- The largest Harvard Bioscience buyer in Q3 2013 was Levin Capital Strategies, an estimated $852K added.
- The largest Harvard Bioscience seller in Q3 2013 was Fidelity Investments, an estimated $7.13M sold.
Based on aggregated 13F filings for Q3 2013.